News Sentiment

TELO sentiment intelligence

Telomir Pharmaceuticals, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 66 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.23 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 58

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

-3.1% over one week, -2.4% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -3.1% Price reacting lower
Trend fit Trend inactive -2.4% over four weeks
Fair value -63.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 42
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 58
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 8
Market source 6
TradingKey 6
Stock Titan 6
ACCESS Newswire 4
Stocktwits 2
The Globe and Mail 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 41
Earnings 20
Deals and strategy 2
Balance sheet 1
Regulatory and legal 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 66
TradingView Direct company coverage

Number of shareholders of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO

This article provides information about the number of shareholders for Telomir Pharmaceuticals, Inc. (NASDAQ: TELO). It indicates that the company's market was closed with no trades at the time of the report. The content mentions that the data is provided by various financial ser

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 07:43
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO

This article provides limited financial information for Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), specifically mentioning its "Price to earnings forward" metric. The displayed content, however, appears to be a stub or a section of a larger financial data service, showing only

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 07:40
Source
TradingView
TradingView Direct company coverage

Telomir Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:TELO)

This article provides financial actuals and estimates for Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), including its current stock price, historical performance, analyst forecasts, and upcoming earnings dates. It also covers market capitalization, volatility, and general investme

Tone
Negative 40/100
Event
Earnings
Published
26 Jun 2026 12:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO

This article provides the "Price to sales forward" financial metric for Telomir Pharmaceuticals, Inc. (NASDAQ: TELO). It lists the company's stock exchange as Nasdaq Stock Market and indicates that the market is currently closed with no trades. The period and value for the price

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 06:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO

This article focuses solely on presenting the "Enterprise value to EBITDA forward" metric for Telomir Pharmaceuticals, Inc. (NASDAQ: TELO). The content provided is minimal, primarily indicating the company's stock market listing and that the market is currently closed with no tra

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 00:10
Source
TradingView
TradingKey Direct company coverage

Telomir Pharmaceuticals Inc (TELO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Telomir Pharmaceuticals Inc (TELO), highlighting its current price momentum score of 4.57 and its position relative to support and resistance levels. It details various technical indicators like MACD, RSI, and moving averages, which c

Tone
Negative 19/100
Event
Market update
Published
24 Jun 2026 16:10
Source
TradingKey
TradingKey Direct company coverage

Telomir Pharmaceuticals Inc (TELO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey reports on Telomir Pharmaceuticals Inc (TELO), noting that relevant data regarding its revenue breakdown by business segments and region, as well as profit contribution, has not yet been disclosed by the company. The article provides basic stock infor

Tone
Negative 40/100
Event
Earnings
Published
20 Jun 2026 07:41
Source
TradingKey
TradingKey Direct company coverage

Telomir Pharmaceuticals Inc (TELO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Telomir Pharmaceuticals Inc (TELO), noting its current valuation score of 6.91, which ranks 143 out of 157 in the Pharmaceuticals industry. The company's P/E ratio is reported as -4.39, significantly below its recent high, while relev

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 03:11
Source
TradingKey
TradingKey Direct company coverage

Telomir Pharmaceuticals Inc (TELO) Institutional Confidence

This article from TradingKey provides an overview of Telomir Pharmaceuticals Inc (TELO)'s institutional confidence based on shareholder activity. It lists key institutional shareholders and changes in their shareholdings, showing that some major holders like Bay Shore Trust and M

Tone
Positive 66/100
Event
Market update
Published
18 Jun 2026 06:09
Source
TradingKey
TradingKey Direct company coverage

Telomir Pharmaceuticals Inc (TELO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Telomir Pharmaceuticals Inc (TELO) currently has no earnings forecast score available from TradingKey, with the Pharmaceuticals industry average being 7.84. Analysts forecast a price target of USD 15.50 for TELO. The company's EPS for the previous quarter was USD -0.06, against a

Tone
Positive 58/100
Event
Earnings
Published
18 Jun 2026 01:10
Source
TradingKey
TradingKey Direct company coverage

Telomir Pharmaceuticals Inc (TELO) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Telomir Pharmaceuticals Inc (TELO), noting its robust financial status but low operating efficiency, with a current financial score of 6.88. The analysis highlights that relevant financial data for various metrics like profitability,

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 01:09
Source
TradingKey
The Daily Corinthian Direct company coverage

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data in Biomedicine & Pharmacotherapy, showcasing Telomir-Zn's ability to restore insulin sensitivity and improve glucose homeostasis in a zebrafish model of Type 2 diabetes. The study demonstrated sig

Tone
Positive 74/100
Event
Market update
Published
16 Jun 2026 00:10
Source
The Daily Corinthian
Investing.com Direct company coverage

Telomir publishes preclinical data on diabetes treatment candidate

Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data for its compound Telomir-Zn, which showed restoration of insulin sensitivity in a zebrafish model of Type 2 diabetes. Despite a 36% share decline over the past year, the clinical-stage biotech com

Tone
Positive 65/100
Event
Market update
Published
15 Jun 2026 12:09
Source
Investing.com
Investing.com Canada Direct company coverage

Telomir publishes preclinical data on diabetes treatment candidate By Investing.com

Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data for its compound Telomir-Zn, demonstrating its ability to restore insulin sensitivity in a zebrafish model of Type 2 diabetes. Despite a 36% share decline over the past year, the company, with a $

Tone
Positive 72/100
Event
Market update
Published
15 Jun 2026 12:09
Source
Investing.com Canada
Stock Titan Direct company coverage

Experimental drug candidate reversed insulin resistance in 14 days — in fish

Telomir Pharmaceuticals announced that its experimental drug candidate, Telomir-Zn, restored insulin sensitivity and improved glucose homeostasis in a preclinical zebrafish model of Type 2 diabetes. The peer-reviewed study, published in Biomedicine & Pharmacotherapy, showed a sig

Tone
Positive 70/100
Event
Market update
Published
15 Jun 2026 12:09
Source
Stock Titan
Stock Titan Direct company coverage

Telomir (NASDAQ: TELO) adds Telomir-Zn diabetes data to support FDA-cleared TNBC trial

Telomir Pharmaceuticals (NASDAQ: TELO) announced new preclinical data for its lead program, Telomir-Zn, published in Biomedicine & Pharmacotherapy. The study showed that Telomir-Zn improved glucose metabolism and insulin resistance in a zebrafish model of Type 2 diabetes, normali

Tone
Positive 67/100
Event
Market update
Published
15 Jun 2026 12:09
Source
Stock Titan
The Globe and Mail Direct company coverage

Telomir Pharmaceuticals Appoints Fractional CFO After Leadership Change

Telomir Pharmaceuticals (TELO) has appointed Andriy Mushak as its fractional Chief Financial Officer through a consulting arrangement with LMAM Consulting Group, following the departure of Alan Weichselbaum. Mushak, a CPA with over 20 years of SEC reporting and audit experience,

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 13:09
Source
The Globe and Mail
Investing.com UK Direct company coverage

Telomir Pharmaceuticals appoints Andriy Mushak as fractional CFO

Telomir Pharmaceuticals has appointed Andriy Mushak as its fractional Chief Financial Officer, effective June 6, following the departure of Alan Weichselbaum. Mushak brings over 20 years of experience in SEC reporting and accounting, and will provide his services through a consul

Tone
Positive 66/100
Event
Market update
Published
09 Jun 2026 23:09
Source
Investing.com UK
Stock Titan Direct company coverage

Telomir Pharmaceuticals (TELO) CFO Andriy Mushak files initial Form 3

Telomir Pharmaceuticals (TELO) Chief Financial Officer Andriy Mushak has filed an initial Form 3, an SEC filing that reports his status as an officer. The filing indicates that Mushak does not currently hold any common stock or derivative securities in the company. This Form 3 ac

Tone
Neutral 50/100
Event
Market update
Published
09 Jun 2026 20:39
Source
Stock Titan
Investing.com South Africa Direct company coverage

Telomir Pharmaceuticals appoints Andriy Mushak as fractional CFO By Investing.com

Telomir Pharmaceuticals has appointed Andriy Mushak as its fractional Chief Financial Officer, effective June 6, following Alan Weichselbaum's departure. Mushak, a partner at LMAM Consulting Group, brings over two decades of experience in SEC reporting and accounting. The company

Tone
Neutral 50/100
Event
Market update
Published
08 Jun 2026 22:39
Source
Investing.com South Africa
Stock Titan Direct company coverage

Telomir Pharmaceuticals (NASDAQ: TELO) taps consultant as new fractional CFO

Telomir Pharmaceuticals announced a change in its finance leadership, appointing Andriy Mushak as the new fractional Chief Financial Officer through LMAM Consulting Group, LLC. This follows the departure of Alan Weichselbaum, which the company states was not due to any disagreeme

Tone
Neutral 50/100
Event
Market update
Published
08 Jun 2026 21:10
Source
Stock Titan
www.marketscreener.com Direct company coverage

Telomir Pharmaceuticals, Inc. Announces CFO Changes, Effective June 6, 2026

Telomir Pharmaceuticals, Inc. announced a change in its Chief Financial Officer position, effective June 6, 2026. Alan Weichselbaum is no longer serving as CFO, and Andriy Mushak has been appointed as the Company's fractional Chief Financial Officer. Mr. Mushak is a Certified Pub

Tone
Neutral 50/100
Event
Market update
Published
08 Jun 2026 21:10
Source
www.marketscreener.com